Ancient reptile tracks rewrite when animals conquered land
Its tracks, which have been discovered in Australia, mean it is the oldest-known vertebrate animal to have permanently abandoned the oceans for dry land, a study suggested on Wednesday.
It also significantly pushes back the date for when these four-limbed pioneers made this important evolutionary step that would eventually lead to humans conquering the globe.
The tracks were found by amateur archaeologists on a 30-centimetre-wide sandstone slab in a mountainous area of the southeastern Australian state of Victoria.
First there was a single footprint of an unknown animal which has "raindrop pockmarks all over it," Per Ahlberg, a palaeontologist at Sweden's Uppsala University, told AFP.
This suggests it was made before the brief shower, said the senior author of a new Nature study describing the discovery.
Then there were two sets of tracks from after the rain.
The second set of tracks suggest this reptile ancestor "was in more of a hurry", he added.
"You see the claws making long scratches on the ground."
- 'Keyholes' into 'lost world' -
The researchers cannot determine whether both sets of tracks were made by the same individual animal, but Ahlberg thinks this is unlikely.
The animal was 60-80 centimetres long and would have looked "quite lizard-like", he added.
That the animal had claws is a clear sign it was an amniote, a group of animals which today includes mammals, birds and reptiles.
Its ancestor tetrapods -- notable for their four limbs -- split into two groups, amniotes and amphibians.
While amphibians had to return to water to lay their eggs, amniotes evolved to have eggs strong enough to survive on land, shedding its last connection to water life.
The discovery indicates that amniotes existed 35 to 40 million years earlier than previously thought, during the turn of the Devonian and Carboniferous periods, the study said.
This suggests the "water-to-land-dwelling transition" may have taken place in just 50 million years, much quicker than had been believed, Stuart Sumida of California State University commented in Nature.
That would be just the latest twist in the tale of how animals rose from the ocean to dominate the land.
"The only way to ever understand it is to look through these tiny little keyholes that we find into this strange, dark, lost world," Ahlberg said.
pcl-dl/jj
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma's oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. Cyclins (including cyclins A and B) are a family of proteins that function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs). Cancers driven by high E2F activity, such as small cell lung cancer (SCLC) and other tumors with RB1 alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. In preclinical models, cyclin A/B RxL inhibitors: Blocked the cyclin A-E2F interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently disrupted the cyclin B-Myt1 interaction, removing a critical safety brake and forcing damaged tumor cells through division, causing tumor cell death. Produced robust anti-tumor activity, including in chemotherapy-resistant SCLC patient-derived xenograft models. The publication, which was co-authored by scientists from Circle Pharma and the Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, can be accessed here (doi: 10.1038/s41586-025-09433-w). 'We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature,' said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. 'This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins. With our first-in-human Phase 1 study of CID-078 well underway, we are eager to see the innovative research outlined in this publication translate into new, high-impact therapeutic options for people living with cancer.' 'These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F-driven cancers, such as cancers with RB1 alterations, which includes nearly all SCLCs, up to half of triple-negative breast cancers, and subsets of other solid tumors,' said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. 'Circle Pharma's cell-permeable, oral macrocycles are designed to overcome the limitations of other therapeutic modalities and are ideally positioned to access cyclins and other historically undruggable targets, offering exciting potential for patients with cancer.' About CID-078, Circle Pharma's Oral Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations. About Circle Pharma Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company's lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at and follow us on LinkedIn and X.
Forbes
4 hours ago
- Forbes
When The Brain Remembers Cold, The Body Burns Fat
Anyone who has shivered through winter knows how powerfully the body responds to cold. But what if simply remembering the cold could trigger the same effect? Cold is one of the oldest forces our bodies have had to reckon with. For mammals, surviving it depends on a delicate coordination between the brain and the body's heat response systems, especially brown adipose tissue, a specialized fat that burns energy to generate heat. A new Nature study from Trinity College Dublin reveals that this ancient survival mechanism can be stored as a memory and reactivated on demand. Mice trained to associate a specific environment with a frigid 4°C chill later mounted the same full-body heat response when placed in that environment at a comfortable 21°C. Their metabolism surged, oxygen consumption increased and brown fat genes switched on: exactly as if they were back in the cold. The effect was traced to 'engram' neurons in the hippocampus, which encodes memory, and the hypothalamus, the brain's temperature-control center. These neurons stored the cold experience and, when activated, signaled the body to turn on its heat-generating systems. When scientists artificially stimulated these neurons with light, the cold-memory effect appeared instantly, even in warm conditions. Silencing them erased the effect entirely. Brown fat is emerging as a critical factor in metabolic health. People with more active brown fat tend to have better glucose control, healthier cholesterol levels and lower risk of obesity and cardiovascular disease. Current strategies to activate brown fat, such as extended cold exposure, are often uncomfortable and impractical. If humans share this memory-based mechanism, it could be possible to design interventions that activate brown fat through sensory cues, immersive environments or targeted brain stimulation, without subjecting people to prolonged cold. Such approaches could open new pathways for treating obesity, type 2 diabetes and age-related metabolic decline. For countless generations, survival hinged not just on fire and shelter, but on the body's ability to anticipate and withstand the freeze. Imagine an early human clan returning each winter to the same windswept valley. Long before the snow fell, the very memory of that place could prime their bodies for hardship, raising metabolism, warming the blood, preparing muscles to endure. Memory was not simply a story of what had happened. It was a tool for survival, reaching deep into the body's physiology. This ancient machinery has not disappeared. It lies within us still, silent but ready to be awakened. This study suggests that the brain's recollection of cold can act as a switch, turning on the metabolic furnace of brown fat even when the surrounding air is mild. In other words, the mind does not just recall the past; it rehearses it in the flesh. The implications stretch far beyond cold itself. Science has already shown that memories of stress can elevate blood pressure, while cherished experiences can bolster immunity. Now, temperature memories join this list, showing how the mind scripts the body's responses. Our inner life is not sealed off from our organs. It writes instructions that ripple through heart, liver, muscle and fat. The challenge ahead is both technical and imaginative. How might we safely harness these circuits? Could a sound, a smell or a virtual landscape serve as a key to unlock the body's hidden stores of resilience? Could physicians prescribe an environment or an experience in the same way they prescribe a pill? To do so would be to redefine medicine itself, turning memory from a passive archive into an active instrument of healing. Our memories, it turns out, are not ghosts of the past. They are levers of the present, tools we may one day learn to wield with precision. What began as an evolutionary trick to survive the cold may become a strategy to live longer, healthier lives. The story of memory is no longer only about who we are; it is about who we might yet become.
CNBC
11 hours ago
- CNBC
Slow progress in Australia's space industry, confident that government will step up: Gilmour Space
Adam Gilmour of Gilmour Space sees more support from the Australian government to speed up progress in the space industry. They also see their competitive advantage being their low cost, and the size of the space industry.
